Anti-Doppel Antibody-Drug Conjugates With Caspase-Cleavable Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) face challenges such as in vivo toxicity, suboptimal target biomarkers, and unpredictable clinical value in cancer treatment due to difficulties in achieving selective targeting of tumor cells without harming normal tissues.
Innovation Solution
Development of anti-doppel antibody-drug conjugates (ADCs) comprising a doppel-targeting moiety, a cleavable linker, and a therapeutic agent, specifically using caspase-cleavable peptide linkers to ensure targeted delivery and release of the chemotherapeutic agent only in tumor cells, minimizing off-target toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional ADCs use tumor-associated antigens (e.g., HER2, TROP2, nectin 4) as target biomarkers, then the ADCs can bind to tumor cells, but they also bind to normal tissues expressing these antigens, causing off-target toxicity
Solution Approach 1:
The patent applies local quality by using doppel, a biomarker that is highly expressed specifically on tumor cells but minimally expressed on normal tissues. This creates a localized targeting effect where the ADC concentrates its action on tumor cells while sparing healthy tissues, thereby resolving the contradiction between achieving reliable tumor binding and avoiding off-target toxicity.
2Reliability
If ADCs use potent cytotoxic drugs to achieve maximum efficacy against tumor cells, then the therapeutic effect is enhanced, but the in vivo toxicity increases
Solution Approach 1:
The patent applies segmentation by dividing the therapeutic system into distinct functional components: a doppel-targeting antibody that provides selective tumor cell recognition and binding, a cleavable linker that enables controlled drug release, and a potent cytotoxic payload that delivers maximum therapeutic effect. This segmentation allows the cytotoxic drug to remain inactive during circulation (reducing in vivo toxicity) while being activated specifically at the tumor site (maintaining therapeutic efficacy).
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-doppel ADCs demonstrate enhanced efficacy and reduced toxicity by selectively targeting tumor cells, with the caspase-cleavable linker amplifying the therapeutic effect and minimizing damage to healthy cells, thereby improving the treatment of doppel-associated cancers.
Implementation Method 1
the caspase-cleavable linker amplifying the therapeutic effect
Data Source
AI summary
Described are anti-doppel antibody-drug conjugates, compositions comprising them, and related methods of treating doppel-associated diseases and conditions, including cancer.